PPBT · Purple Biotech Ltd.

Purple Biotech's Q1 2026 results reflect a strategic pivot to the CAPTN-3 platform, with R&D expenses increasing 50% YoY to $1.2 million driven by CMC development for IM1240 and IM1305, signaling accelerated preclinical progress toward 2027 first-in-human studies. G&A expenses rose 67% to $1.0 million due to higher payroll and professional services, contributing to an adjusted operating loss of $2.1 million, up from $1.3 million last year. However, strong finance income of $2.2 million from warrant fair value changes narrowed the GAAP net loss to just $0.1 million, a significant improvement. CEO Gil Efron highlighted new patient-derived tumor data from Mount Sinai validating IM1240's tri-specific design (capped-CD3 × 5T4 × NKG2A), which demonstrated universal activity in resistant samples like PD-1 resistant head and neck cancer and enfortumab vedotin-resistant bladder cancer, with the NKG2A arm enhancing efficacy and therapeutic index. The formation of a CAPTN-3 SAB and expanded AI collaboration with Converge Bio bolster platform expansion. With $6.4 million in cash, the company has visibility into 2027, though further CAPTN-3 advancement and potential partnering for CM24/NT219 remain critical for sustaining momentum.